top of page

GLOBAL DEAL SYNDICATION

HBS Alumni Angels syndicates selected deals across the full global membership of its 14 chapters. This enables selected deals from one chapter to reach a global network of accredited investor alumni. This is a unique benefit of being a member in a local HBS Alumni Angel chapter. Investment decisions are made and executed individually following a global webinar. Once investments are made, investors often assist companies in other areas as formal or informal advisers. For details on how the process works, please scroll down.

UPCOMING SYNDICATION CALLS

20250710 Stratagen logo.jpg

GLOBAL SYNDICATED INVESTMENT PRESENTATION:
STRATAGEN BIO

Thursday, July 10, 2025 9am PT, 12pm ET, 5pm London, 6pm Continental Europe

Presenter:
CEO & Co-Founder, Greg Ekchian, PhD
​
For HBS Angels Members ONLY

 

On behalf of the Boston chapter, we would like to share the following investment opportunity:
 

STRATAGEN BIO: Transforming MRI into a tool for quantitative biomarker assessment and objective clinical decision-making.

​

Stratagen Bio (Boston, MA) is transforming existing MRI scanners into quantitative, objective, and biological measurement platforms. Standard MRI scans are only capable of visual and morphological interpretation, often providing a highly subjective and potentially misleading assessment of disease. Our platform unlocks the power of quantitative MRI which enables an objective and quantitative assessment of tissue composition, structure, and function. We leverage standard MRI hardware and software to achieve rapid, harmonized, accurate, and workflow-compatible measurements. Our go-to-market is focused in prostate cancer where MRI is heavily used but still provides poor quality outcomes including a high rate of unnecessary biopsies. Our platform could be used to avoid unnecessary procedures, improve diagnostic accuracy, and reduce MRI scan session duration.  

​

Executive Summary

Stratagen Bio is transforming existing MRI scanners into quantitative, objective, and biological measurement platforms - starting with prostate cancer. Stratagen is a clinical-stage company based in Boston, MA and operates out of the Pagliuca Harvard Life Lab on the Harvard Business School campus.

​

Unmet Clinical Need

Relying on standard qualitative MRI data to support clinical decision-making often leads to an incomplete and/or misleading understanding of disease. The quality of these assessments frequently relies heavily on the experience level and sub-specialty training of the radiologist.

​

This is acutely obvious in prostate cancer where MRI is used heavily prior to biopsy for patients with a suspicion of cancer (e.g. elevated prostate specific antigen blood test). There are about 1.3M men annually in the US suspected of having prostate cancer. The initial introduction of qualitative MRI in the workflow was to address two challenges, the high false positive rate of PSA blood tests, which sent many patients to biopsy unnecessarily. While the initial introduction of qualitative MRI in prostate cancer did improve outcomes for patients (28% reduction in biopsy), there remains a very high rate of avoidable prostate biopsies. Westphalen et al. found that, on average, only 35% of prostate biopsies yield clinically significant cancer and this rate ranges from 20% to 70% depending on the radiologist conducting the reads.

​

This causes a continued high rate of unnecessary biopsies which is extremely undesirable to patients due to the risk for pain, nerve damage, and infection. It is also expensive for payers, motivating them to support methods and approaches to enable the safe deferral of biopsies.

​

Stratagen Bio Product Summary

Our approach utilizes the quantitative version of the parameters that are already evaluated qualitatively (T1 and T2 relaxation time and Apparent Diffusion Coefficient). We are building an MRI vendor agnostic platform and leverage standard MRI hardware and software to strategically collect data that can be converted to quantitative MRI data. Unlike standard qualitative MRI data, quantitative MRI data, in principle, is on a ground truth absolute scale. This enables objective thresholds to be set for each quantitative MRI parameter to distinguish between different tissue types, assess tissue health, and evaluate the extent of disease.
 

We are building an end-to-end pipeline that:

  1. Qualifies the MRI scanner in the quantitative domain

  2. Uses vendor agnostic and commercial acquisition programs

  3. Produces high precision quantitative MRI measurements

  4. Converts this data into a synthesized and biologically actionable format

  5. Seamlessly integrates with the existing clinical workflow.

​

Traction

Stratagen Bio launched a clinical trial at Dana-Farber/Brigham and Women’s Hospital in June 2025 focused on the MRI assessment conducted in preparation for prostate radiation therapy and has a clinical trial imminently kicking off at the University of Rochester focused on the diagnostic prostate MRI. Stratagen has a strong pipeline of additional hospitals, including letters of intent, to participate in our clinical trials and has ongoing negotiations with additional leading private practice groups and academic medical centers. Stratagen Bio was named a Grand Prize Winner of the 2024 Harvard President’s Innovation Challenge.
 

Market Opportunity

Our go-to-market in prostate cancer is a $1.3B market opportunity domestically. This is based on bottom-up market calculation ($1,000 per patient x 1.3M patient per year). The bottom-up market sizes for the broader market are $40B (US) and $100B (WW). While our initial focus is in prostate cancer, our platform is highly transferable to other indications in oncology as well as neurology and neurodegeneration.
 

Leadership and Team

Stratagen Bio was co-founded by Dr. Gregory Ekchian and Professor Michael Cima. Dr. Ekchian completed his PhD and Postdoctoral Fellowship at MIT, where he focused on extracting more biologically actionable information from MRI. Following his postdoc, he was a Blavatnik Fellow for Life Science Entrepreneurship at Harvard Business School. Professor Cima is a tenured faculty member at MIT, the former Dean for Innovation, and a serial life science entrepreneur with multiple successful exits including two acquisitions by Johnson and Johnson and one IPO. Our team has grown to include Dr. Nick Zwart with 20 years of experience in MRI including building MRI systems and MR-based diagnostics and Dr. Sydney Sherman who holds a PhD from MIT in medical engineering and has developed MR-based diagnostic systems.
 

Strategic Advisory Board

  • Dr. Paul Nguyen – Executive Vice Chair of Radiation Oncology, Mass General Brigham

  • Dr. Daniel Margolis – Radiologist (Prostate MRI), Weill Cornell

  • Dr. Larry Tanenbaum – Former VP and CTO, RadNet

  • Dr. Joe Frassica – Former CMO, Philips North America

  • Gunnar Schaefer – Former CTO and Co-Founder, FlyWheel

Greg Ekchian, PhD

CO-FOUNDER & CEO

20250710 Ekchian-cube 200X.jpg

Greg Ekchian, PhD, is an entrepreneur, engineer, and innovator. He has spent his career at the interface of academic research and life science start-ups. Greg is currently the co-founder and CEO of Stratagen Bio, where they are transforming MRI into an objective, quantitative, and biological measurement platform, starting with prostate cancer. He was previously awarded the Blavatnik Fellowship in Life Science Entrepreneurship at Harvard Business School and the Kavanaugh Translational Innovation Fellowship at the Massachusetts Institute of Technology. Greg was also named to MIT Technology Review’s 35 Innovators Under 35 in 2020. He holds a BS in Biomedical Engineering from Boston University and an MEng and PhD in Materials Science and Engineering from the Massachusetts Institute of Technology.

The Zoom Meeting information will be in your registration confirmation email.
Please check your junk/spam/bulk folders if you don't see it.

UPCOMING

20250724 Thermology Health logo_edited.jpg

GLOBAL SYNDICATED INVESTMENT PRESENTATION:
STRATAGEN BIO

Thursday, July 24, 2025 9am PT, 12pm ET, 5pm London, 6pm Continental Europe

Presenter:
CEO Yuval Yashiv
​
For HBS Angels Members ONLY

 

On behalf of the London chapter, we would like to share the following investment opportunity:

 

Thermology Health

The first and only platform capable of medical-grade thermal imaging accuracy, Thermology Health is a UK/US medtech  startup pioneering early detection of diabetic complications. Born out of a decade of research at the UK’s National Physical Laboratory (NPL - one of the world’s top metrology institutes), Thermology Health is translating advanced thermal imaging technology – originally developed for space and nuclear industries – into a life-saving solution to prevent diabetic amputations.

​

Executive Summary: Thermology Health Overview

Building on world-class science, Thermology Health has developed an AI-powered remote monitoring platform that revolutionizes how clinicians detect diabetic foot ulcers before they become limb-threatening. Recently spun -out from NPL led by CEO Yuval Yashiv (London Business School alumnus and serial medtech entrepreneur), Thermology Health is leveraging its unique high-precision thermal imaging system to address a critical gap in diabetes care.

By providing an early-warning, Thermology’s platform helps healthcare providers prevent costly amputations, improve patient outcomes, and reduce hospital burden – tackling one of the most urgent challenges in diabetes care today affecting millions of lives and costing over $40 billion p.a. in the US alone.

​

Unmet Need

Diabetic foot ulcers (DFUs) represent a silent healthcare crisis, leading to ~150,000 amputations per year in the US and ~9,000 in the UK. Of the 37 million adult diabetics in the US, over 20% - 7 million people – are at high-risk of diabetic foot ulcers and will get a DFU in their lifetime. This translates to 1.6 million DFU in the US every year.

Treating DFUs is extremely expensive ($43 billion annually in the US) and outcomes are poor – five-year mortality rates of approx. 30% (comparable to all-cancers), and 50% of patients dying within two years after a major amputation (a rate surpassed only by lung cancer). Physicians currently detect foot ulcers too late, resulting in preventable disability and death. There is a critical need for a way to catch early signs of ulcers before they progress: studies show that well over 60% of diabetic foot ulcers could be avoided with early detection and simple interventions (e.g. rest, orthotics, antibiotics). The challenge has been achieving frequent, accurate monitoring at home – something not feasible with standard care until now.

​

Diabetic foot ulcers also contribute to health inequality with the most deprived patient population having 1.82 times more amputations than the least deprived patients, with ethnic minorities affected in particular.

​

Technology Platform

International clinical guidelines call for “Daily monitoring of foot temperature to look for signs of inflammation”. To date, this has been a wholly unachievable task.

Thermology Health addresses this gap with a precision thermal imaging solution for preventative care. Thermology Health is building an AI-driven platform to remotely monitor foot temperature patterns and to detect subtle warning signs of ulcers 2–6 weeks before clinical symptoms appear. It combines a patient-friendly device with powerful cloud analytics:

  • High-Accuracy Thermal Scanner: Patients scan their feet at home using a specialized thermal camera that measures temperature within ±0.2°C accuracy – meeting medical-grade standards (ISO 80601-2-56).

  • AI Diagnostic Algorithms: Each scan generates over 70,000 highly accurate temperature data points per foot. Thermology is developing algorithms to analyze these heat maps to identify abnormal hotspots and asymmetries (e.g. looking for ≥4°F differences between feet) that indicate inflammation or developing ulcers.

  • Alerts & Reporting: The system flags concerning temperature changes and sends real-time alerts to clinicians. It generates easy-to-read reports and trend analyses, enabling doctors to intervene early (often with simple measures) before an ulcer forms.

  • Cloud Integration: All data is uploaded to a secure cloud platform, integrated with electronic medical records. Clinicians can remotely track patients’ foot health over time via a dashboard, while machine learning will continuously improve the predictive accuracy as more data is collected.

 

This end-to-end platform empowers proactive care: an early warning system that provides actionable insights for physicians to prevent serious complications.

​

Market Opportunity

By preventing ulcers and amputations, Thermology Health’s solution can save lives and significantly reduce healthcare costs. The addressable market is vast and under-served: tens of millions of high-risk diabetics worldwide could benefit from routine thermal monitoring. Despite this $20B+ global opportunity, no dominant competitor exists – other technologies are beginning to make in-roads, but Thermology’s solution has distinct and unique advantages over competitor systems. These include: accuracy, portability, whole foot coverage (most systems cover the soles only, missing 50% of potential ulcers) and AI potential (AI data requires high-fidelity data), leaving the market wide open for Thermology Health. In our initial target markets (US, UK, EU) alone, ~14 million high-risk diabetic patients translate to a $7.7B serviceable market for Thermology’s platform.

  • TAM: ~$25B+ globally (high-risk diabetic patients requiring preventive foot monitoring).

  • SAM: ~$7.7B focused on high-risk diabetics in the US, UK, and EU (≈14M patients * ~$540/year per patient).

  • SOM: ~$1B+ directly reachable in the near term through initial focus on specific settings and on leading podiatry/endocrinology clinics and healthcare networks in the US and UK (our pilot and partnership channels).

 

Traction & Momentum

  • Deep R&D and IP: Technology developed and validated over 10 years at NPL. To the best of our knowledge, Thermology’s device is the most accurate medical thermal imaging system of its kind (±0.2°C), with a patent granted in the US and UK (pending in EU, China, India, Japan, Canada). Developed at NPL, a paper published in a study with King’s College Hospital, London showed that the technology is reliable and accurate compared with “gold standard” single-point medical thermometers.

  • Non-Dilutive Funding: Backed by significant grant support – $5M awarded by the UK government – underscoring the confidence in Thermology’s solution. Spun out from NPL in April,2025 (https://www.npl.co.uk/news/saving-lives-through-early-foot-ulcer-detection)

  • Clinical Pilots Underway: Pilot trials will commence over the summer at multiple sites, including an NHS hospital in London and two healthcare facilities in the US. Early clinical feedback is positive and very encouraging.

  • Proven Impact Potential: External studies have demonstrated that high-frequency temperature monitoring can reduce ulcer incidence by over 60%. This is formalised in Recommendation #7 of the Preventative Guidelines issued by the International Working Group of the Diabetic Foot (IWGDF) – the highest international authority in this area.

  • Team & Support: As detailed below, the company is led by industry veterans with a strong track record and actively supported by the  top leadership and subject-matter experts at NPL. This has enabled partnerships and early customer conversations both in the US and in the UK.

 

Competitive Edge

 No direct competitor offers a solution with the same combination of accuracy, foot coverage, portability and AI potential. In addition, the technology has multiple modalities with potential in additional areas such as: Pressure Ulcers; Chronic Wound Care; Surgical Incision Infections. Each of these areas is a large market in its own right and represents an opportunity for Thermology’s system.
 

More specifically, the key advantages are:

  • Non-Contact & Comprehensive Foot Coverage: Unlike other competitors, which are contact devices with hygiene requirements, concerns over pressure, and lack of ability to scan the whole foot, Thermology Health is non-contact and provides whole-foot coverage.

 

  • Multi-Modality & Versatile Use Cases: Other competitors are a single-modality product for at-home, soles-only use (therefore DFU-only). Thermology Health supports multiple modalities, fitting clinical, semi-clinical and home settings. Thermology also offers broader use cases beyond just DFUs, including pressure ulcer detection, monitoring of ulcer healing and monitoring of Surgical Incision Infections. Each of these represent multi-billion dollar markets in their own right.

 

  • Portability & B2B Appeal: Thermology Health is a smaller and more portable device, making it practical for larger care settings. This, combined with its technical precision and multi-usage capability, makes it significantly more attractive for B2B medical distribution, which should add a premium to its valuation.
    While some competitors have had success with some US providers, we see the presence of competitors as a positive sign, as it helps validate the market and eases the reimbursement journey for thermal monitoring technology in general.

 

Business Model

  • Recurring Revenue – Remote Monitoring Service: Thermology operates as a B2B2C remote patient monitoring service. Clinics and physicians enroll their high-risk diabetic patients onto the platform, and Thermology will charge approximately a monthly fee per patient for continuous monitoring. These fees are largely reimbursable under existing Medicare RPM (Remote Patient Monitoring) reimbursement codes, making it budget-neutral for clinics, affordable for patients and, importantly, incentivizing for physicians.

  • Scalable Economics: The model is highly scalable and capital-efficient. Each physician typically enrols 50-100 patients, which can generate roughly $1,600 per patient per year in total reimbursement revenue. With a concentrated base of specialist physicians treating many at-risk patients, Thermology can grow revenue rapidly while keeping sales and distribution costs low.

 

Go-to-Market Strategy

  • Pilot to Pipeline: Thermology’s initial go-to-market focuses on a specific clinical setting of with a concentration of relevant patients in the US and specialist diabetes hospital settings in the UK. We will leverage pilot results and endorsements from key opinion leaders (e.g. renowned Vascular Surgeons, Podiatrists and Diabetologists) to build credibility and demand. Early adopters in our pilot sites will serve as reference accounts, demonstrating reimbursement and improved patient care to attract additional providers and payors. We expect FDA clearance later this year – as a Class 1 device this does not involve the regulatory burden seen in other medical areas.

  • Scaling with Partners: Following successful pilots, Thermology will expand to broader healthcare settings and to the ultimate goal of home settings. We’ll be looking to partner with Remote Care companies, which is a high-growth area both in the US and in the UK/EU. Initially starting out in the US, Thermology will replicate successful strategies in the UK as a second market and major EU markets as a third market. With key competitive advantages and the backing of NPL’s global reputation, Thermology is uniquely positioned to become the standard of care for diabetic foot monitoring globally.

 

Leadership & Team

Thermology Health is led by an all-star team with deep technical and industry expertise. The whole team is comprised of executives with no less than 15 years’ experience in their respective fields.

​

CEO Yuval Yashiv is a veteran tech entrepreneur with 25 years of experience and two successful tech exits (including a prior medtech startup acquired by FTSE 100 firm Halma), an IPO on London’s Junior Market, and VC experience from an early-stage London-based firm. An Electrical & Electronics Engineer by background, Yuval has an MBA from London Business School.

​

Chief Medical Officer, Dr Paul Hayes is a former senior Vascular Surgeon at the renowned Addenbrooke’s Hospital in Cambridge with a record of over 20 clinical trials and over 150 peer-reviewed publications.  Over the past 6 years Paul has transitioned to CMO roles in early-stage med-tech companies and has the unique combination of clinical expertise and commercial med-tech experience.

​

Chief Commercial Officer, John Strobel has 30 years commercial experience in the US med-tech industry. John served as Global VP Sales & Marketing of Ohio-based Volk Optical over 12 years, as it grew to become one of the best known brands in Ophthalmology worldwide. Over his career John held commercial roles in a variety of med-tech companies in multiple clinical areas. John holds a BS in Biomedical Engineering from Tulane University, and an MBA from Thunderbird.

​

Aside from the presenting team, other members include a Symbolic AI specialist with a unique track record in medical devices and an imaging specialist also with many years of med-tech experience across multiple medical technology companies.

​

Between them, the team have the key essential ingredients of any med-tech company: technology, clinical and business expertise coupled with real-world experience. Most of the team members have worked together previously.
 

Thermology is also supported by notable advisors and board members – including NPL’s CFO, a highly experienced med-tech investor and a former tech advisor to the UK government – who bring additional credibility and networks in both healthcare and venture communities.

​

Fundraising

Thermology Health did a first-close of its pre-seed round in April (of which one HBSAA UK member invested over  $200,000). As a result of interest from Harvard Business School Angels, the Board has agreed to keep this round open on the same terms until the end of August, exclusively for HBS Angels. This investment will enable Thermology to undergo initial pilot trials and to obtain regulatory clearance from the FDA.

Yuval Yashiv

CEO

20250724 Thermology Health - Yashiv 2.png

Yuval Yashiv is the Founder and Chief Executive Officer of Thermology Health. He previously worked at Eurovestech PLC as an Operating Partner. Yuval Yashiv attended London Business School.

​​

MORE INFORMATION COMING SOON! 

Dr Paul Hayes

CHIEF MEDICAL OFFICER

20250724 Thermology Health - Hayes.png

​

​​

MORE INFORMATION COMING SOON! 

John Strobel

CHIEF COMMUNICATIONS OFFICER

20250724 Thermology Health - Strobel.jpg

​

​​

MORE INFORMATION COMING SOON! 

The Zoom Meeting information will be in your registration confirmation email.
Please check your junk/spam/bulk folders if you don't see it.

PREVIOUS SYNDICATION CALL

20250605 Moxie Logo 2025.png

GLOBAL SYNDICATED INVESTMENT PRESENTATION:
MOXIE SCRUBS

Thursday, June 5, 2025 9am PT, 12pm ET, 5pm London, 6pm Continental Europe

Presenter:
CEO & Founder, Alicia Tulsee, Harvard BLA'15
​
For HBS Angels Members ONLY

 

Follow-on Round

On behalf of the Boston chapter, we would like to share the following investment opportunity:

​

The first and only brand inspired and designed by nurses, Moxie Scrubs is proud to be a woman-owned, minority-owned Boston-based start-up, born in a taxi cab and Harvard’s Innovation Lab.

 

Executive Summary: Moxie360, Moxie Scrubs’ Expansion Company Overview

Building on the multi-million dollar success of Moxie Scrubs, the brand has expanded into digital health with Moxie360: An AI-powered workforce enablement platform revolutionizing how hospitals support, engage, and retain their nursing staff.
 

Incubated at Harvard Innovation Labs and founded by Harvard Alum, Alicia Tulsee – Moxie360 expands the brand’s deep connection with over 1 million nurses into the Healthtech space, helping hospitals retain their nurse workforce, improve patient outcomes, and drive financial performance: three of the most urgent challenges in healthcare today.


Market Opportunity

Burnout is driving nurses away from the bedside, with 80% reporting excessive stress and a 23% higher risk of patient fatality from workforce fatigue, exacerbated by poor nurse staffing to patient ratios. This nurse attrition crisis costs hospitals billions annually, ranging from $40k to $60 per nurse! 
 

Moxie360 is a complete healthcare solution designed to ease the day-to-day burdens on nurses, delivering a proven 78% increase in hospital nurse retention and access to industry-leading medical resources that is proven to increase positive patient outcomes. Leveraging the trust built through Moxie Scrubs, Moxie’s existing nurse customers have become champions of Moxie360, fueling demand and adoption within hospital systems nationwide.
 

  • TAM: $123B+ across medical apparel, nursing education, and workforce solutions
     

  • SAM: $5B+ focused on tech-forward U.S. nurses in middle- and lower-tier hospital systems
     

  • SOM: $1B+ directly accessible through Moxie’s established D2C nurse and hospital relationships
     

Traction & Momentum
 

  • 300+ hospitals on waitlist for Moxie360
     

  • First pilot launching May 2025 at the nation’s largest public health system, executed LOI toward a minimum $450k contract, upwards of $900k
     

  • Moxie Scrubs Projected $6M revenue in 2025, with $2M ARR in B2B contracts for 2026
     

  • Moxie360 Mentorship program with proven 78% increase in nurse retention among early hospital adopters
     

  • 4:1+ LTV:CAC on medical apparel business with only 1% return rate, first order profitable
     

Business Model
 

  • Moxie360 Platform: Sold to hospitals through a per-user license model, with 3-year renewable contracts
     

  • Moxie Scrubs: Sold D2C to nurses (who are required to buy 6–7 sets annually), supporting customer acquisition and promotes brand trust
     

Go-to-Market Strategy
 

Moxie is uniquely positioned to bridge the gap between hospital systems and individual nurses through trusted brand equity, multiple revenue channels, a rapidly scaling waitlist, and first mover advantage. The platform’s roadmap includes expanding to 100 hospitals within three years, leveraging existing hospitals and union partnerships, and deep nurse engagement with the Moxie Scrubs brand through social media channels.
 

Leadership & Team
 

Led by an all-star team with experience growing billion-dollar brands (Wayfair, Chewy, Kenneth Cole, Juicy Couture, Nordstrom, Good American, AB-InBev to name a few) and digital healthcare innovators serving millions of users today: Moxie360 brings together deep technical, clinical, and operational expertise.

​

Revenue Updates
 

  1. We’re proud to share that we received an LOI for a PO valued at $6 million MSRP for 2025 through our new retail partner!
    For those asking about tariffs — we’re fortunate that they have only increased our landed COGS by $1. 

  2. $370k+ revenue since relaunching Scrubs in April Zero marketing. We’re on track to hit $1M in revenue by the end of Q2

  3. With the close of our fundraise, we project $2M D2C in Moxie Scrubs revenue this year and $2M in Moxie360 contracts from hospital partners already in our pipeline, separate from $6M retail partner

  4. Moxie Scrubs just launched on Target.com 

  5. Moxie360 launches in the country's largest healthcare system this month, against a minimum $450k contract, with 300 hospitals on our waitlist!
     

Fundraising
 

Moxie is raising a $1M Angel Seed round via SAFE at a $13M post-money valuation cap, with $800K already committed. This investment will unlock four hospital contracts already in Moxie’s pipeline, driving $2M in ARR through Moxie360, and upwards of $6M in Moxie Scrubs medical apparel sales.

​

Alicia Tulsee

FOUNDER & CEO, HBS BLA 2015

20250605 Moxie Alicia Tulsee.JPG

Alicia Tulsee is a native New Yorker and Harvard alum based in Boston, MA and is the founder of the first direct to consumer medical apparel brand for nurses, Moxie Scrubs. Alicia graduated from Harvard University with a degree in economics in 2015 and has expertise in consumer packaged goods, entertainment, and nonprofits. Alicia previously spearheaded national marketing for brands like Budweiser and AB InBev portfolio brands in emerging markets, FreshPure Waters, and others. In the music industry, Alicia worked in event planning and management, copy-writing, working directly with artists.

In awe of all of the amazing nurses who cared for her loved ones, Alicia felt a calling to do something meaningful for the nursing profession and founded Moxie Scrubs out of Harvard University’s Innovation Lab with the passion to create a brand dedicated to giving nurses the sense of fashion, professionalism, and respect that they want and deserve.

Today, Alicia has received acclaim as an impact entrepreneur in Forbes, ForbesWomen, Nasdaq, Entrepreneur Magazine, and others.

PAST SYNDICATED COMPANIES

20250605 moxie scrubs - moxie360 2
20250410 Osteoboost
20250116 Soteri Skin logo
20241121 VonVascular_Logo_Color
20241117 SUNRAYscientific-NewLogo
20240919 pathotrak
20240905 SYND CO2_Split 1280 × 720
20210614 MomiBaby logo cropped
20221117 Agile Devices HIRES_edited
20240229 WURQ Logo1
20240201 Nuvio Mobility
20231219 pente_logo
20221011 Moxie_Scrubs_Logo NEW_edited
20230727 Mercator logo
20230715 Fuego logo
20230323 Measure Studio logo hi-res 300X90
20230126 Avadain Logo tm
20210614 MomiBaby logo cropped
20221201 EarthGrid_COLOR 200X50
20221117 Agile Devices HIRES_edited
20221110 Epilogue Systems logo
20221011 Moxie_Scrubs_Logo NEW_edited
20220922 TANG app 400X210
20220908 Beckon-FullLogo 400X252
20220531 SurgiBox logo 200X133
20220523 Alleviate-Therapy 200X
20220425 egs-logo
20220413 Eunimart logo 300X
20220201 Lingrove
20210906 Moxie_Scrubs_Logo 500X135
20210819 Landsdowne Labs
20210722 RocketStar
20210614 MomiBaby logo cropped
20210527 Cognoptix logo 200X36
20210427 Synd Call LUPII_LOGO 200X
20210121 TANG app 2 150X
20201209 Wave logo 200X
20201203 Beckon logo
20201119%20Syndication%20Dover%20Microsy
20200826 New View logo
20200813%2520COLORONLY%2520logo_edited_e
20200811 BrightSpec Logo
unnamed
Wheeli
Vaporox
Cargo Chief
MyndBlue
Health Hero
agencyQ
HIPAAtrek
IrriGreen
SIA
Tire Agent
Wibmo

HOW IT WORKS

Use arrows on the side to navigate

1. HOST CHAPTER

A company must meet a threshold of member investment in one of our HBS Alumni Angel Chapters listed here. The leadership of the host chapter nominates the company for global syndication and provides a local member contact to act as syndication lead and a company contact.

CRITERIA

Ideally, for global syndication a company should meet the following requirements:

  • Local host chapter members committed to invest at least $50,000* and local chapter forwards deal to global for syndication; 

  • Company assures at least $50,000-100,000 investible capacity;

  • Company provides at least 2 weeks for due diligence following the webinar, prior to requiring an investment decision;

  • Minimum individual investment amount is set at $25,000 or less;

  • Company agrees to a one-time admin fee of $1500.

The Global Syndication Committee selects the most suitable company candidates from the 15 participating HBSAA chapters and is aiming to host monthly webinars. 

​

*NY and other larger chapters may have a $100,000 min.

HBS Alumni Angels Association
© Copyright HBS Alumni Angels Association
ALL RIGHTS RESERVED.

  • Instagram
  • Facebook - Black Circle
  • Twitter - Black Circle
  • LinkedIn - Black Circle
bottom of page